ProQR Therapeutics
Leiden
About ProQR Therapeutics
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $451.7M
- Funding stage: IPO
- Last round: Grant (Jan 2026)
- Ticker: nasdaq:PRQR
- Website: proqr.com
- Phone: 0031-0854894932
Industries & Categories
Biotechnology, Genetics, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/proqr-therapeutics-52175 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.